Jamjoom Pharmaceuticals Factory (4015) Fundamentals 2026 — P/E 21.5x, Revenue Analysis | SniperIQ
Jamjoom Pharmaceuticals Factory (4015) is a SA-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of SAR 10.3B, trading at SAR 146.60 on the SAU. This SniperIQ fundamentals page covers Jamjoom Pharmaceuticals Factory's valuation (P/E 21.5x, P/B 5.9x), profitability (net margin 31.2%), revenue (SAR 1.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jamjoom Pharmaceuticals Factory's market cap?
Jamjoom Pharmaceuticals Factory (4015) has a market capitalization of approximately SAR 10.3B, trading at SAR 146.60 on the SAU. Market cap moves with the live share price.
What is Jamjoom Pharmaceuticals Factory's P/E ratio?
Jamjoom Pharmaceuticals Factory's trailing twelve-month P/E ratio is 21.5x, with a price-to-book (P/B) of 5.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jamjoom Pharmaceuticals Factory?
Jamjoom Pharmaceuticals Factory runs a net profit margin of 31.2%, a gross margin of 62.6%, and an operating margin of 32.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jamjoom Pharmaceuticals Factory generate?
Jamjoom Pharmaceuticals Factory reported revenue of SAR 1.5B for fiscal year 2025, with net income of SAR 464M and earnings per share (EPS) of 6.6. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jamjoom Pharmaceuticals Factory pay a dividend?
Jamjoom Pharmaceuticals Factory offers a trailing dividend yield of about 2.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jamjoom Pharmaceuticals Factory financially healthy?
Jamjoom Pharmaceuticals Factory carries a debt-to-equity ratio of 0.01x and a current ratio of 4.94x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jamjoom Pharmaceuticals Factory a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jamjoom Pharmaceuticals Factory (4015) the key facts are: market cap SAR 10.3B, P/E 21.5x, revenue SAR 1.5B, 52-week range 125-179.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jamjoom Pharmaceuticals Factory's full fundamentals live
Get Jamjoom Pharmaceuticals Factory's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.